Daniel P. Walker

Discovery of<i>N</i>-[(3<i>R</i>)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-<i>c</i>]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia:  Synthesis and Structure−Activity Relationship

Donn G. Wishka, Daniel P. Walker, Karen M. Yates et al. · Journal of Medicinal Chemistry · 2006 · 188 citations · Full text

Neuropsychology, Compound 14, Psychopharmacology +23

Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design

Seungil Han, Anil Mistry, Jeanne S. Chang et al. · Journal of Biological Chemistry · 2009 · 107 citations · Full text

Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora

Ken Blount, Cynthia M. Megyola, Mark S. Plummer et al. · Antimicrobial Agents and Chemotherapy · 2015 · 100 citations · Full text

Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists

Daniel P. Walker, Donn G. Wishka, David W. Piotrowski et al. · Bioorganic & Medicinal Chemistry · 2006 · 94 citations

Structure–activity Relationship, Vivo Activity, Biochemistry +8

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

Daniel P. Walker, Michael P. Zawistoski, Molly A. McGlynn et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 86 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Signal Transduction +11